Carumonam

Carumonam (AMA-1080; Ro 17-2301) is a sulfonated monocyclic β-Lactam Antibiotic, targeting to penicillin-binding protein (PBP) . Carumonam exerts highly activity against Enterobacteriaceae, Pseudomonas aeruginosa, and Haemophilus influenzae, while it weakly and even inactively inhibits Streptococcus pneumoniae and Staphylococcus aureus. Carumonam is resistant to beta-lactamase-mediated hydrolysis[1].

Product Specifications

CAS Number

[87638-04-8]

Product Name Alternative

AMA-1080; Ro 17-2301

UNSPSC

12352005

Target

Antibiotic; Bacterial; Penicillin-binding protein (PBP)

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/carumonam.html

Solubility

10 mM in DMSO

Smiles

O=C(CO/N=C(C(N[C@H]1[C@H](N(C1=O)S(=O)(O)=O)COC(N)=O)=O)/C2=CSC(N)=N2)O

Molecular Formula

C12H14N6O10S2

Molecular Weight

466.40

References & Citations

[1]Imada A, et al. In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic. Antimicrob Agents Chemother. 1985 May;27 (5) :821-7. |[2]Kita Y, et al. Comparative pharmacokinetics of carumonam and aztreonam in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother. 1986 Jan;29 (1) :127-34.